Published in Cancer Res on June 01, 1999
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature (2014) 5.45
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res (2011) 2.81
Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A (2001) 2.44
Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol (2008) 2.35
Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res (2011) 2.25
Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol (2014) 2.23
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene (2012) 1.98
Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol (2003) 1.89
Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One (2012) 1.89
Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene (2013) 1.86
Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A (2005) 1.73
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer (2008) 1.73
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res (2009) 1.71
Myc confers androgen-independent prostate cancer cell growth. J Clin Invest (2003) 1.65
Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol (2003) 1.64
Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinase. J Biol Chem (2011) 1.60
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer (2015) 1.55
Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci U S A (2001) 1.43
Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol (1999) 1.36
Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol (2006) 1.33
Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research. PLoS One (2011) 1.32
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene (2014) 1.31
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.29
Androgen receptor signaling and mutations in prostate cancer. Asian J Androl (2010) 1.27
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res (2014) 1.27
Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res (2013) 1.26
Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol (2012) 1.25
Cancer research meets evolutionary biology. Evol Appl (2009) 1.24
Mechanisms of the development of androgen independence in prostate cancer. World J Urol (2005) 1.23
The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol (2008) 1.21
Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int (2005) 1.19
Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate (2010) 1.19
Yin Yang 1 regulates the transcriptional activity of androgen receptor. Oncogene (2009) 1.15
Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin (2014) 1.15
The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol (2011) 1.14
Androgen receptor functional analyses by high throughput imaging: determination of ligand, cell cycle, and mutation-specific effects. PLoS One (2008) 1.13
Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors. ACS Chem Biol (2009) 1.13
The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am (2011) 1.13
Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J (2010) 1.11
Berberine suppresses androgen receptor signaling in prostate cancer. Mol Cancer Ther (2011) 1.11
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res (2014) 1.07
Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proc Natl Acad Sci U S A (2003) 1.01
Molecular pathways and targets in prostate cancer. Oncotarget (2014) 1.00
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab (2010) 1.00
Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. Cancer Res (2006) 0.99
Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor. J Biol Chem (2010) 0.98
Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol (2014) 0.96
Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R. Am J Pathol (2004) 0.96
NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant (2010) 0.95
The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol (2003) 0.95
Differential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptor. PLoS One (2013) 0.94
A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab (2008) 0.94
Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer. Mol Cancer Res (2014) 0.94
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol (2016) 0.93
Androgen regulation of the androgen receptor coregulators. BMC Cancer (2008) 0.92
Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR). Biochem J (2004) 0.92
The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity. PLoS One (2012) 0.92
Small molecule inhibitors as probes for estrogen and androgen receptor action. J Biol Chem (2010) 0.92
AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther (2013) 0.91
The isolation and identification of apolipoprotein C-I in hormone-refractory prostate cancer using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Asian J Androl (2009) 0.90
Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk. Neoplasia (2003) 0.90
Identification of androgen-coregulated protein networks from the microsomes of human prostate cancer cells. Genome Biol (2003) 0.89
Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H. J Biol Chem (2009) 0.88
The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. Chem Biol Interact (2014) 0.88
Acquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation. Environ Health Perspect (2005) 0.88
Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. Oncotarget (2015) 0.87
Androgen receptor gene mutation, rearrangement, polymorphism. Transl Androl Urol (2013) 0.87
Androgen receptor variation affects prostate cancer progression and drug resistance. Pharmacol Res (2016) 0.87
Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer. Clin Cancer Res (2016) 0.87
Acquiring Metastatic Competence by Oral Squamous Cell Carcinoma Cells Is Associated with Differential Expression of α-Tubulin Isoforms. J Oncol (2012) 0.86
Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells. Urol Res (2004) 0.86
Membrane androgen binding sites are preferentially expressed in human prostate carcinoma cells. BMC Clin Pathol (2003) 0.86
MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer. Mol Cancer (2011) 0.86
Antiandrogens in prostate cancer. Invest New Drugs (1999) 0.86
The androgen receptor in hormone-refractory prostate cancer. Asian J Androl (2008) 0.85
Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation. Int J Biol Sci (2014) 0.85
Diastereomers of the brominated flame retardant 1,2-dibromo-4-(1,2 dibromoethyl)cyclohexane induce androgen receptor activation in the hepg2 hepatocellular carcinoma cell line and the lncap prostate cancer cell line. Environ Health Perspect (2009) 0.84
Androgens and prostate cancer. World J Urol (2003) 0.84
Persistent androgen receptor addiction in castration-resistant prostate cancer. J Hematol Oncol (2015) 0.84
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. Clin Med Insights Oncol (2016) 0.83
Circumventing anti-androgen resistance by molecular design. J Am Chem Soc (2007) 0.83
Interaction of organophosphate pesticides and related compounds with the androgen receptor. Environ Health Perspect (2003) 0.83
Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cells. Mol Biol Cell (2015) 0.82
In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer. Mol Endocrinol (2012) 0.82
NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth. Invest New Drugs (2009) 0.81
Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Devel Ther (2012) 0.81
Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol (2012) 0.81
The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy. Curr Drug Targets (2013) 0.80
The biology of castration-resistant prostate cancer. Curr Probl Cancer (2014) 0.80
Structure-based virtual screening and identification of a novel androgen receptor antagonist. J Biol Chem (2012) 0.80
Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC). J Steroid Biochem Mol Biol (2015) 0.80
Contemporary agents in the management of metastatic castration-resistant prostate cancer. Can Urol Assoc J (2016) 0.79
Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer. Mol Cancer Ther (2014) 0.79
Proteomic-coupled-network analysis of T877A-androgen receptor interactomes can predict clinical prostate cancer outcomes between White (non-Hispanic) and African-American groups. PLoS One (2014) 0.79
Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer. PLoS One (2013) 0.79
Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells. Oncotarget (2014) 0.78
Is there an anti-androgen withdrawal syndrome for enzalutamide? World J Urol (2014) 0.77
Basic science of hormonal therapy for prostate cancer. Rev Urol (2001) 0.77
Androgen receptor aberrations in the era of abiraterone and enzalutamide. World J Urol (2015) 0.76
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med (1995) 6.26
Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J Exp Med (1993) 4.80
The idiopathic hypereosinophilic syndrome. Blood (1994) 4.65
Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature (1998) 4.10
Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells. J Exp Med (1997) 3.74
Recognition of cluster of differentiation 1 antigens by human CD4-CD8-cytolytic T lymphocytes. Nature (1989) 3.49
Height and risk of death among men and women: aetiological implications of associations with cardiorespiratory disease and cancer mortality. J Epidemiol Community Health (2000) 3.23
Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. Science (1998) 2.76
CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J Exp Med (1999) 2.53
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res (2000) 2.28
Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells. Gastroenterology (1997) 2.21
Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol (2001) 2.20
Actin-containing matrix associated with the plasma membrane of murine tumour and lymphoid cells. Nature (1981) 2.12
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res (1996) 2.04
Expression of murine CD1 on gastrointestinal epithelium. Science (1990) 2.00
Birth weight of offspring and mortality in the Renfrew and Paisley study: prospective observational study. BMJ (1997) 1.85
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol (2001) 1.81
Expression of a nonpolymorphic MHC class I-like molecule, CD1D, by human intestinal epithelial cells. J Immunol (1991) 1.75
Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology (2000) 1.75
Esophageal squamous papillomas. A clinicopathologic study of 38 lesions and analysis for human papillomavirus by the polymerase chain reaction. Am J Surg Pathol (1993) 1.74
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res (2001) 1.72
Human intestinal intraepithelial lymphocytes are derived from a limited number of T cell clones that utilize multiple V beta T cell receptor genes. J Immunol (1993) 1.71
Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol (2001) 1.71
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res (2001) 1.71
The natural history of chronic obstructive pulmonary disease. Eur Respir J (2006) 1.66
Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300. Cancer (1999) 1.65
Cell-by-cell scanning of whole mitochondrial genomes in aged human heart reveals a significant fraction of myocytes with clonally expanded deletions. Nucleic Acids Res (1999) 1.64
Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res (1997) 1.62
Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N Engl J Med (1992) 1.61
Detection of clonal immunoglobulin gene rearrangements by polymerase chain reaction amplification and single-strand conformational polymorphism analysis. Am J Pathol (1993) 1.56
A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J Immunol (2001) 1.47
CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology (2000) 1.46
CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus. J Leukoc Biol (2001) 1.44
Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci U S A (2001) 1.43
Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab (2001) 1.42
BK-related polyomavirus vasculopathy in a renal-transplant recipient. N Engl J Med (2001) 1.41
Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens. J Surg Oncol (1994) 1.40
Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol (1999) 1.36
Human T-cell receptor (TCR) alpha/beta + CD4-CD8- T cells express oligoclonal TCRs, share junctional motifs across TCR V beta-gene families, and phenotypically resemble memory T cells. Proc Natl Acad Sci U S A (1993) 1.32
CD1d is involved in T cell-intestinal epithelial cell interactions. J Exp Med (1993) 1.31
SRY interacts with and negatively regulates androgen receptor transcriptional activity. J Biol Chem (2001) 1.26
Human T cells expressing an invariant V alpha 24-J alpha Q TCR alpha are CD4- and heterogeneous with respect to TCR beta expression. Hum Immunol (1997) 1.22
High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol (1998) 1.20
Tissue distribution of the non-polymorphic major histocompatibility complex class I-like molecule, CD1d. Immunology (1993) 1.18
A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res (2001) 1.18
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol (2001) 1.13
Biochemical characterization of CD1d expression in the absence of beta2-microglobulin. J Biol Chem (1999) 1.12
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol (1997) 1.11
Structure and function of the CD1 family of MHC-like cell surface proteins. Immunol Rev (1995) 1.11
Independent association of angiogenesis index with outcome in prostate cancer. Clin Cancer Res (2001) 1.08
Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 genes. Nucleic Acids Res (1997) 1.08
Distribution of dominant T cell receptor beta chains in human intestinal mucosa. J Exp Med (1994) 1.07
Immunolocalization of CD1d in human intestinal epithelial cells and identification of a beta2-microglobulin-associated form. Int Immunol (1999) 1.07
Persistent clonal expansions of peripheral blood CD4+ lymphocytes in chronic inflammatory bowel disease. J Immunol (1996) 1.06
Relapsing acute myeloid leukemia manifesting as hypopyon uveitis. Am J Ophthalmol (1995) 1.05
Low concentrations of vancomycin stimulate biofilm formation in some clinical isolates of Staphylococcus epidermidis. J Clin Pathol (2009) 1.04
Evidence of T cell receptor beta-chain patterns in inflammatory and noninflammatory bowel disease states. Am J Physiol (1999) 1.03
Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J Urol (1996) 1.02
Diagnosis and control measures of the 2010 outbreak of foot-and-mouth disease A type in the Republic of Korea. Transbound Emerg Dis (2012) 1.02
A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer (2000) 1.01
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol (2009) 1.01
Rapid identification of uropathogenic Escherichia coli of the O25:H4-ST131 clonal lineage using the DiversiLab repetitive sequence-based PCR system. Clin Microbiol Infect (2009) 1.00
Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol (1990) 0.99
IFN-gamma modulates CD1d surface expression on intestinal epithelia. Am J Physiol (1996) 0.99
Heterogeneity of NK1.1+ T cells in the bone marrow: divergence from the thymus. J Immunol (1999) 0.98
Intraepithelial lymphocytes in normal human intestine do not express proteins associated with cytolytic function. Am J Pathol (1997) 0.98
Salivaricin 9, a new lantibiotic produced by Streptococcus salivarius. Microbiology (2011) 0.97
Nonclassical behavior of the mouse CD1 class I-like molecule. J Immunol (1997) 0.97
Prevalence and distribution of plasmid-mediated quinolone resistance genes in clinical isolates of Escherichia coli lacking extended-spectrum beta-lactamases. J Antimicrob Chemother (2008) 0.96
HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol (2001) 0.96
Separating in-utero and postnatal influences on later disease. Lancet (1999) 0.95
Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers. Curr Pharm Biotechnol (2004) 0.95
A critical tyrosine residue in the cytoplasmic tail is important for CD1d internalization but not for its basolateral sorting in MDCK cells. J Immunol (1999) 0.95
Enhancing the Viability of Lactobacillus plantarum Inoculum by Immobilizing the Cells in Calcium-Alginate Beads Incorporating Cryoprotectants. Appl Environ Microbiol (1990) 0.94
Frequent abnormalities of TSG101 transcripts in human prostate cancer. Oncogene (1997) 0.94
Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocr Relat Cancer (2007) 0.94
How accurately do adult sons and daughters report and perceive parental deaths from coronary disease ? J Epidemiol Community Health (2000) 0.94
Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Curr Oncol (2013) 0.93
Androgen regulation of soluble guanylyl cyclasealpha1 mediates prostate cancer cell proliferation. Oncogene (2006) 0.93
Antigen presentation by intestinal epithelial cells. Immunol Lett (1999) 0.91
ASAP. Atypical small acinar proliferations. Hum Pathol (1999) 0.90
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Ann Oncol (2008) 0.90
Chromium(VI) treatment of normal human lung cells results in guanine-specific DNA polymerase arrest, DNA-DNA cross-links and S-phase blockade of cell cycle. Carcinogenesis (1996) 0.90
Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology (1998) 0.90
Effects of Bloom's syndrome fibroblasts on genetic recombination and mutagenesis of herpes simplex virus type 1. Somat Cell Mol Genet (1987) 0.89
Malignant germ cell tumors in men infected with the human immunodeficiency virus: natural history and results of therapy. J Clin Oncol (1995) 0.88
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J Clin Oncol (2001) 0.88
Salivary gland neoplasia in the dog and cat: survival times and prognostic factors. J Am Anim Hosp Assoc (2001) 0.88
A common TCR beta-chain expressed by CD8+ intestinal mucosa T cells in ulcerative colitis. J Immunol (1996) 0.86
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol (2013) 0.84
Regional loss of chromosome 6 in two urological malignancies. Cancer Res (1989) 0.83
Effects of joint effusion on proprioception in patients with knee osteoarthritis: a single-blind, randomized controlled clinical trial. Osteoarthritis Cartilage (2010) 0.83